Tesamorelin is a synthetic 44-amino-acid analog of Growth Hormone–Releasing Hormone (GHRH).

Mechanism of action

•Binds to pituitary GHRH receptors

•Stimulates pulsatile endogenous growth hormone (GH) release

•Increases IGF-1 levels

•Leads to:

•Increased lipolysis (fat breakdown)

•Improved metabolic signaling

•Protein synthesis effects

Studied / clinical effects

•Reduction of visceral adipose tissue (VAT)

•Improvements in lipid profiles

•Potential reduction of liver fat (NAFLD research)

•Investigational cognitive and aging research via GH/IGF-1 restoration

Regulatory status clarification

•FDA-approved as a prescription medication for reduction of excess abdominal fat in HIV-associated lipodystrophy.

•Some research-grade products sold online are labeled “research only,” but that refers to vendor classification — not the molecule itself.

⸻

Reconstitution math (educational reference)

You described:

•Vial: 10 mg tesamorelin

•Added: 2.0 mL bacteriostatic water

Resulting concentration

Final solution concentration:

✅ 5 mg per mL

In clinical trials and approved therapeutic use:

👉 Common studied dose:

•2 mg once daily (subcutaneous)

(This is the most widely used standardized dose in HIV lipodystrophy trials and many research protocols.)

Average research dose marking:

40 units on a U-100 syringe